abemaciclib

a cell cycle inhibitor

Also Known As:

5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine; 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)pyrimidin-2-yl)amine; LY-2835219; LY2385219; LY2835210; LY2835219; Verzenio; abemaciclib mesylate

Networked: 487 relevant articles (86 outcomes, 127 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Toi, Masakazu: 17 articles (01/2022 - 09/2017)
2.	Tolaney, Sara M: 12 articles (01/2022 - 01/2016)
3.	Martin, Miguel: 11 articles (08/2022 - 01/2016)
4.	Sledge, George W: 11 articles (01/2022 - 09/2017)
5.	Goetz, Matthew P: 10 articles (01/2022 - 11/2017)
6.	Frenzel, Martin: 10 articles (12/2020 - 01/2016)
7.	Masuda, Norikazu: 9 articles (01/2022 - 09/2017)
8.	Sohn, Joohyuk: 9 articles (01/2022 - 09/2017)
9.	Huober, Jens: 8 articles (08/2022 - 11/2017)
10.	Barriga, Susana: 8 articles (03/2021 - 09/2017)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2022 - "In the randomized clinical trial monarchE, treatment with adjuvant abemaciclib combined with ET demonstrated a clinically meaningful improvement in IDFS and DRFS for patients with HR+, ERBB2-, node-positive, high-risk early breast cancer who received NAC before trial enrollment. " 07/16/2023 - "BACKGROUND The efficacy of abemaciclib in high-risk patients with early-stage HR+/Her2- breast cancer has been verified by MonarchE. " 01/01/2023 - "Results in early breast cancer are discordant, with sustained improvement in invasive disease-free survival demonstrated for abemaciclib but not other CDK4/6 inhibitors to date. " 01/01/2019 - "Abemaciclib is an effective and well-tolerated treatment for HR-positive, HER2-negative advanced or metastatic breast cancer." 11/01/2017 - "First-Line Abemaciclib Effective in ER+ Breast Cancer."
2.	Neoplasms (Cancer) 08/23/2023 - "We found that combining abemaciclib with PD-1 inhibition reduced tumor burden and improved overall survival in mice. " 01/01/2020 - "Our data suggested that Abemaciclib can be utilized as a novel therapeutic agent in ATC cancer. " 01/01/2021 - "In this study, we investigated the efficacy of abemaciclib using preclinical GC models representing defined molecular subtypes from The Cancer Genome Atlas. " 01/01/2022 - "These insights may help to optimize the clinical development of abemaciclib, especially for the treatment of brain malignancies." 01/15/2017 - "Here, we found that LY2835219 remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo. "
3.	Diarrhea 02/23/2023 - "In our real-world analysis, we observed a higher incidence of diarrhea related to abemaciclib compared to data from clinical trials, and a higher rate of permanent treatment discontinuation due to gastrointestinal toxicity. " 02/23/2023 - "We aimed to determine whether the incidence of abemaciclib-induced diarrhea in real-world trials was higher than the one reported in clinical trials, where patients are highly selected, and to evaluate the success rate of standard supportive care in this setting. " 11/01/2023 - "Patients in groups A (79%) and B (78%) who received abemaciclib experienced similar rates of diarrhea. " 03/01/2023 - "The safety profile of abemaciclib is characterized by frequent gastrointestinal toxicity, especially diarrhea. " 03/01/2023 - "Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data."
4.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2020 - "Methods: In this study, we first assessed the antitumor efficacy of abemaciclib, an FDA-approved CDK4/6i, in a syngeneic murine ovarian cancer model. " 01/01/2020 - "Results: We observed that abemaciclib monotherapy could enhance immune infiltration, especially CD8+ T cell and B cell infiltration, in the ID8 murine ovarian cancer model. " 03/07/2022 - "Interestingly, the efficacy of ZC-22 is even higher than the combination of PARPi Olaparib and CDK4/6i Abemaciclib in most breast and ovarian cancer cells, suggesting that it may be an effective alternative for the PARPi and CDK4/6i combination therapy. " 01/01/2016 - "Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non-small cell lung cancer, colorectal cancer, and ovarian cancer. "
5.	Disease Progression 01/01/2023 - "The results were sensitive to the cost of abemaciclib, disease progression utility, and patients' age. " 09/01/2017 - "Abemaciclib 200 mg was administered orally on a continuous schedule every 12 hours until disease progression or unacceptable toxicity. " 01/01/2020 - "Time to second disease progression (median, 23.1 months vs 20.6 months), time to chemotherapy (median, 50.2 months vs 22.1 months), and chemotherapy-free survival (median, 25.5 months vs 18.2 months) were also statistically significantly improved in the abemaciclib arm vs placebo arm. " 03/24/2021 - "These results highlight the need for future studies to confirm molecular predictors of cross-resistance to CDK4/6i therapy and to better characterize the utility of abemaciclib after disease progression on prior CDK4/6i." 10/01/2023 - "Abemaciclib was discontinued in 86% of patients after a median of 7.7 months (13.2 months for combination therapy and 7.0 months for monotherapy) mainly due to disease progression (69%). "

Related Drugs and Biologics

1.	Hormones (Hormone)
2.	ribociclib
3.	palbociclib
4.	Fulvestrant (Faslodex)
5.	ErbB Receptors (EGF Receptor)
6.	Cyclin-Dependent Kinase 4
7.	Aromatase Inhibitors
8.	human ERBB2 protein
9.	Letrozole (Femara)
10.	Cyclin-Dependent Kinases (cdk Proteins)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Neoadjuvant Therapy
5.	Drug Tapering